{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* The boronic acids 2(S)-amino-6-boronohexanoic acid (ABH) and S-(2-boronoethyl)-L- cysteine (BEC) are potent inhibitors of both ARG isoforms at physiologic pH (with binding constant (KD) of approximately 0.3 mM), binding with much higher affinity than the natural substrate (L-arginine K<sub>m</sub> is 5 mM) (Ash et al., 2004; Christianson et al., 2005).\n* Human ARG1 was crystallized in association with both inhibitors and new insights into the catalytic mechanism have been gained (Di Costanzo et al., 2005), with L-arginine K<sub>m</sub> of 5 mM. \n* The boronic acid 2(S)-amino-6-boronohexanoic acid (ABH) has a binding constant (KD) of approximately 0.3 mM."}
{"final_json": [{"molecule_name": "2(S)-amino-6-boronohexanoic acid (ABH)", "protein_target_name": "ARG", "binding_metric": "KD", "value": "0.3", "unit": "mM", "is_logarithmic": false}, {"molecule_name": "S-(2-boronoethyl)-L-cysteine (BEC)", "protein_target_name": "ARG", "binding_metric": "KD", "value": "0.3", "unit": "mM", "is_logarithmic": false}, {"molecule_name": "L-arginine", "protein_target_name": "ARG", "binding_metric": "Km", "value": "5", "unit": "mM", "is_logarithmic": false}, {"molecule_name": "2(S)-amino-6-boronohexanoic acid (ABH)", "protein_target_name": "ARG1", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "L-arginine", "protein_target_name": "ARG1", "binding_metric": "Km", "value": "5", "unit": "mM", "is_logarithmic": false}, {"molecule_name": "2(S)-amino-6-boronohexanoic acid (ABH)", "protein_target_name": null, "binding_metric": "KD", "value": "0.3", "unit": "mM", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n3. An antigen-binding protein according to any one of the preceding clauses, wherein the antigen-binding protein binds trimeric human ARG2 with a dissociation constant ( D) of less than 10 nM, less than 1 nM, less than 500 pM, less than 300 pM, or less than 150 pM, when assessed by Bio-Layer Interferometry (BLI)."}
{"final_json": [{"molecule_name": null, "protein_target_name": "trimeric human ARG2", "binding_metric": "D", "value": "<10 nM", "unit": "nM", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": "trimeric human ARG2", "binding_metric": "D", "value": "<1 nM", "unit": "nM", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": "trimeric human ARG2", "binding_metric": "D", "value": "<500 pM", "unit": "pM", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": "trimeric human ARG2", "binding_metric": "D", "value": "<300 pM", "unit": "pM", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": "trimeric human ARG2", "binding_metric": "D", "value": "<150 pM", "unit": "pM", "is_logarithmic": false}]}
{"raw_mentions": "All affinity-matured scFv antibodies tested in this experiment showed improvements in IC50 compared to parent C0020187 scFv.\nAll affinity- matured scFv antibodies tested in this experiment showed improvements in IC50 compared to parent C0020187 scFv.\nAll clones inhibited the activity of THP-1 lysate derived human trimeric ARG2 with improved IC50 values compared to parent recombinant human lgG1 C0020187.\nAll clones inhibited the activity of THP-1 lysate derived human trimeric ARG2 with improved IC50 values compared to the first generation lead recombinant human lgG1 C0021061."}
{"final_json": [{"molecule_name": "C0020187 scFv", "protein_target_name": null, "binding_metric": "IC50", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "C0020187 scFv", "protein_target_name": null, "binding_metric": "IC50", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "C0020187", "protein_target_name": "ARG2", "binding_metric": "IC50", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "C0021061", "protein_target_name": "ARG2", "binding_metric": "IC50", "value": null, "unit": null, "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In brief, for the first round of solution-phase selections, biotinylated human ARG2 in Dulbecco\u2019s phosphate buffered saline (DPBS, pH 7) was added (final concentration of 100 nM biotinylated human ARG2) to purified phage particles that had been pre-incubated for 1 hour in Marvel-PBS (3% w/v) containing Streptavidin-coupled paramagnetic beads (Dynabeads\u00ae M280, Invitrogen Life Sciences, UK).\n* Two subsequent rounds of selection were carried out as previously described but with a reduced concentration of biotinylated ARG2 antigen, specifically 50 nM and 25 nM of biotinylated human ARG2 at round 2 and round 3, respectively.\n* This was followed by the addition of 5 mI of 12 nM recombinant human trimeric ARG2 enzyme, 5 mI of 6.67 nM streptavidin cryptate and 5 mI 40 nM anti-c-myc-XL665."}
{"final_json": [{"molecule_name": null, "protein_target_name": "ARG2", "binding_metric": null, "value": "100", "unit": "nM", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": "ARG2", "binding_metric": null, "value": "50", "unit": "nM", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": "ARG2", "binding_metric": null, "value": "25", "unit": "nM", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": "ARG2", "binding_metric": null, "value": "12", "unit": "nM", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "6.67", "unit": "nM", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "40", "unit": "nM", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nIC50 values were determined by testing a dilution series of the purified scFv, prepared in TBS, in the ARG2 enzyme inhibition assay described in section 1.5, substituting the unpurified scFv periplasmic preparation with the purified scFv.\nIC50 values were determined by testing a dilution series of the ARG2 specific recombinant IgGi, prepared in TBS, in the ARG2 enzyme inhibition assay described in section 1.5, substituting the unpurified scFv periplasmic preparation with the ARG2 specific recombinant IgGi.\nTo determine ECso\u2019s of test antibodies, a dilution series was created in sterile TBS at 8X the final assay concentration was added to the assay plate containing cells."}
{"final_json": [{"molecule_name": null, "protein_target_name": "ARG2", "binding_metric": "IC50", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "ARG2 specific recombinant IgGi", "protein_target_name": "ARG2", "binding_metric": "IC50", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "test antibodies", "protein_target_name": null, "binding_metric": "EC50", "value": null, "unit": null, "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nIC50 values were determined by testing a dilution series of the ARG2 specific recombinant IgGi, prepared in TBS.\nARG2 specific recombinant IgGi were tested alongside N-Hydroxyl-L-Arginine (a small molecule competitive inhibitor of ARG2) as a positive control and NIP228 (irrelevant isotype control antibody) as a negative control. \n* Graphical plot of NHLA had the top two concentration data points excluded, the maximum % proliferation value corresponds to a concentration of 0.444 mM."}
{"final_json": [{"molecule_name": "N-Hydroxyl-L-Arginine", "protein_target_name": "ARG2", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "NIP228", "protein_target_name": null, "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "NHLA", "protein_target_name": null, "binding_metric": null, "value": "0.444", "unit": "mM", "is_logarithmic": false}, {"molecule_name": "ARG2 specific recombinant IgGi", "protein_target_name": "ARG2", "binding_metric": "IC50", "value": null, "unit": null, "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nA series of dilutions of the C0020187 Fab (3.25 - 240 nM) were individually placed in contact with the ligand surface for a sufficient amount of time to observe sensorgrams that could be fitted to an appropriate binding model with confidence (typically 5 minutes), followed by an appropriate length of dissociation time (typically 10 minutes).\nTable 9. Affinity Data for C0020187 and ARG2 interaction \nFour point titrations of C0020187 IgG (10, 3, 1 and 0.3 mM) were set up in the presence of 11 concentrations of arginine (500, 400, 300, 200, 125, 75, 50, 25, 17, 10 and 5 mM) and the reaction allowed to proceed for 80, 60, 45, 30, 15 or 5 minutes before the addition of the urea detection reagents O-Phthaldialdehyde and N-(1-Napthyl)ethylenediamine."}
{"final_json": [{"molecule_name": "C0020187 Fab", "protein_target_name": null, "binding_metric": null, "value": "3.25 - 240", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "C0020187", "protein_target_name": "ARG2", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "C0020187 IgG", "protein_target_name": null, "binding_metric": null, "value": "10, 3, 1, 0.3", "unit": "mM", "is_logarithmic": false}, {"molecule_name": "arginine", "protein_target_name": null, "binding_metric": null, "value": "500, 400, 300, 200, 125, 75, 50, 25, 17, 10, 5", "unit": "mM", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n* Table 11. IC50 values (M) for clones in scFv format in 187 IgG epitope competition assay (Figure 8)\n* Table 12. IC50 values (M) for clones in scFv format in trimeric human ARG2 EIA \n* The potency of each purified scFv was determined by testing a dilution series of the scFv (typically 4 pM - 1200 nM) in the epitope competition assay described above.\n* The potency of each purified scFv was determined by testing a dilution series of the scFv (typically 4 pM - 1200 nM) in the enzyme inhibition assay described in section 1.5."}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "binding_metric": "IC50", "value": null, "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": "ARG2", "binding_metric": "IC50", "value": null, "unit": "M", "is_logarithmic": false}, {"molecule_name": "scFv", "protein_target_name": null, "binding_metric": null, "value": "4 pM - 1200 nM", "unit": null, "is_logarithmic": false}, {"molecule_name": "scFv", "protein_target_name": null, "binding_metric": null, "value": "4 pM - 1200 nM", "unit": null, "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* To determine the IC50 values of test antibodies, a dilution series of the test antibodies were created in TBS and 5 pi were added to 10 mI lysate / human plasma mixture (1.15 mg/ml lysate, 25% (v/v) urea depleted human plasma and 20 mM MnCh and incubated for 2 hours at room temperature in a 384 well plate.\n* Data points were plotted and IC50 values determined using a four parameter fit in GraphPad Prism (Figure 11 , Table 13).\n* C50 values are averaged data from n=2 experiments. \n\nNote that the text does not provide explicit numeric values with units for the bioactivity metrics. However, the sentences mention the determination of IC50 values, which implies that the values are provided in Table 13, but the table is not included in the text snippet."}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "binding_metric": "IC50", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "IC50", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "C50", "value": null, "unit": null, "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nAntibodies were tested alongside N-Hydroxyl-L-arginine (a small molecule competitive inhibitor of ARG2) as a positive control and CEA6 (irrelevant isotype control antibody) as a negative control (Figure 13, Table 18).\nThe affinities of the second-generation antibodies to human ARG2 were measured on the OctetRED system, with an analyte range of 1.8 to 120 nM."}
{"final_json": [{"molecule_name": "N-Hydroxyl-L-arginine", "protein_target_name": "ARG2", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "CEA6", "protein_target_name": null, "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": "human ARG2", "binding_metric": null, "value": "1.8 to 120", "unit": "nM", "is_logarithmic": false}]}
